TCM Biotech International (TPE:4169) Piotroski F-Score: N/A (As of Aug. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:4169 TCM Biotech International Corp TPE:4169
52 GF Score
Price NT$157.00
GF Value NT$42.31
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is TCM Biotech International Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

TCM Biotech International has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for TCM Biotech International's Piotroski F-Score or its related term are showing as below:

During the past 13 years, the highest Piotroski F-Score of TCM Biotech International was 7. The lowest was 1. And the median was 2.

TCM Biotech International  (TPE:4169) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


TCM Biotech International Piotroski F-Score Related Terms


TCM Biotech International Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for TCM Biotech International's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TCM Biotech International Piotroski F-Score Chart

TCM Biotech International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.00 2.00 2.00 6.00 7.00

TCM Biotech International Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 7.00 N/A 7.00 N/A

TPE:4169 vs VRTX, REGN, RVMD: Piotroski F-Score Comparison

For the Biotechnology subindustry, TCM Biotech International's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TCM Biotech International Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TCM Biotech International's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where TCM Biotech International's Piotroski F-Score falls into.


TPE:4169
52GF Score
TCM Biotech International Corp TPE:4169
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 9.227 + 7.736 + -4.419 + -26.34 = NT$-13.8 Mil.
Cash Flow from Operations was -5.098 + 11.713 + 27.699 + -5.419 = NT$28.9 Mil.
Revenue was 182.546 + 172.664 + 174.988 + 172.891 = NT$703.1 Mil.
Gross Profit was 85.644 + 78.02 + 77.346 + 77.192 = NT$318.2 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(0 + 1213.91 + 1179.12 + 1204.175 + 1270.178) / 5 = NT$1216.84575 Mil.
Total Assets at the begining of this year (Mar25) was NT$0.0 Mil.
Long-Term Debt & Capital Lease Obligation was NT$13.0 Mil.
Total Current Assets was NT$929.5 Mil.
Total Current Liabilities was NT$143.2 Mil.
Net Income was 0 + 13.668 + -2.511 + 6.626 = NT$17.8 Mil.

Revenue was 0 + 164.694 + 171.897 + 155.293 = NT$491.9 Mil.
Gross Profit was 0 + 78.841 + 81.093 + 75.979 = NT$235.9 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Mar25) was
(1322.922 + 1269.857 + 0 + 1182.358 + 0) / 5 = NT$1258.379 Mil.
Total Assets at the begining of last year (Dec23) was NT$1,322.9 Mil.
Long-Term Debt & Capital Lease Obligation was NT$0.0 Mil.
Total Current Assets was NT$0.0 Mil.
Total Current Liabilities was NT$0.0 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

TCM Biotech International's current Net Income (TTM) was -13.8. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

TCM Biotech International's current Cash Flow from Operations (TTM) was 28.9. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-13.796/0
=

ROA (Last Year)=Net Income/Total Assets (Dec23)
=17.783/1322.922
=0.01344221

TCM Biotech International's return on assets of this year was . TCM Biotech International's return on assets of last year was 0.01344221. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

TCM Biotech International's current Net Income (TTM) was -13.8. TCM Biotech International's current Cash Flow from Operations (TTM) was 28.9. ==> 28.9 > -13.8 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=12.957/1216.84575
=0.01064802

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Mar25
=0/1258.379
=0

TCM Biotech International's gearing of this year was 0.01064802. TCM Biotech International's gearing of last year was 0. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=929.474/143.172
=6.49200961

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=0/0
=

TCM Biotech International's current ratio of this year was 6.49200961. TCM Biotech International's current ratio of last year was . ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

TCM Biotech International's number of shares in issue this year was 58.533. TCM Biotech International's number of shares in issue last year was 60.236. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=318.202/703.089
=0.45257713

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=235.913/491.884
=0.47961105

TCM Biotech International's gross margin of this year was 0.45257713. TCM Biotech International's gross margin of last year was 0.47961105. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=703.089/0
=

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=491.884/1322.922
=0.37181633

TCM Biotech International's asset turnover of this year was . TCM Biotech International's asset turnover of last year was 0.37181633. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+0+1+0+1+1+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

TCM Biotech International has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Is TCM Biotech International (TPE:4169) Overvalued in 2026?

Based on GuruFocus' analysis, TCM Biotech International stock appears to be overvalued. The current stock price of NT$157.00 is trading 271.1% above its estimated GF Value™ of NT$42.31. GuruFocus considers TCM Biotech International to be Significantly Overvalued.

Key valuation signals for TPE:4169:

  • Piotroski F-Score: N/A
  • GF Value™: NT$42.31 vs. price of NT$157.00 (271.1% above fair value)
  • GF Score™: 52/100 with 3 warning signs

No single metric tells the full story. See the TPE:4169 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TCM Biotech International Business Description

Address No. 97, Section 1, Xintai 5th Road, 24th Floor-8, Xizhi District, Neihu District, Taipei, TWN, 221416
TCM Biotech International Corp is a Taiwan based biotechnology company. It is engaged in research and development of new biotech drugs, development of microbial strain cultivation and fermentation technology, biotechnology services, wholesale of medical equipment, and sales of functional foods. Its products includes medical equipment, medical testing platform, medical drugs, and others. The Group has two reportable segments: Segment A and Segment B. Segment A is the functional foods segment, while Segment B is the pharmaceuticals segment. It derives maximum revenue from pharmaceuticals segment. Geographically, the company operates in Taiwan and Other countries, of which it generates maximum revenue from Taiwan.
52GF Score

Get the complete analysis for TPE:4169

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$157.00
Price
NT$42.31
GF Value